171 related articles for article (PubMed ID: 10566008)
1. Batimastat. BB 94, collagenase inhibitors-1.
Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
[No Abstract] [Full Text] [Related]
2. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
[TBL] [Abstract][Full Text] [Related]
3. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.
Talbot DC; Brown PD
Eur J Cancer; 1996 Dec; 32A(14):2528-33. PubMed ID: 9059343
[No Abstract] [Full Text] [Related]
4. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
Brown PD
Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
[TBL] [Abstract][Full Text] [Related]
6. AG 3340.
Drugs R D; 1999 Feb; 1(2):137-8. PubMed ID: 10566007
[No Abstract] [Full Text] [Related]
7. BAY12-9566. BAY 12 9566, BAY12 9566.
Drugs R D; 1999 Feb; 1(2):142-3. PubMed ID: 10566009
[No Abstract] [Full Text] [Related]
8. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
9. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
Parsons SL; Watson SA; Steele RJ
Eur J Surg Oncol; 1997 Dec; 23(6):526-31. PubMed ID: 9484924
[TBL] [Abstract][Full Text] [Related]
10. CGS 27023A. CDG 27023A.
Drugs R D; 1999 Feb; 1(2):144-5. PubMed ID: 10566010
[No Abstract] [Full Text] [Related]
11. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.
Beattie GJ; Smyth JF
Clin Cancer Res; 1998 Aug; 4(8):1899-902. PubMed ID: 9717817
[TBL] [Abstract][Full Text] [Related]
12. AE 941--Neovastat.
Drugs R D; 1999 Feb; 1(2):135-6. PubMed ID: 10566006
[No Abstract] [Full Text] [Related]
13. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
14. The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells.
Erba E; Ronzoni S; Bassano L; Giavazzi R; D'Incalci M
Ann Oncol; 1999 May; 10(5):589-91. PubMed ID: 10416010
[No Abstract] [Full Text] [Related]
15. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Macaulay VM; O'Byrne KJ; Saunders MP; Braybrooke JP; Long L; Gleeson F; Mason CS; Harris AL; Brown P; Talbot DC
Clin Cancer Res; 1999 Mar; 5(3):513-20. PubMed ID: 10100701
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake bothrops asper.
Escalante T; Franceschi A; Rucavado A; Gutiérrez JM
Biochem Pharmacol; 2000 Jul; 60(2):269-74. PubMed ID: 10825472
[TBL] [Abstract][Full Text] [Related]
17. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
18. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
Dabrowska A; Giermasz A; Marczak M; Gołab J; Jakóbisiak M
Anticancer Res; 2000; 20(1A):391-4. PubMed ID: 10769685
[TBL] [Abstract][Full Text] [Related]
19. Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.
Holst-Hansen C; Low JA; Stephens RW; Johnson MD; Carmeliet P; Frandsen TL; Brünner N; Dickson RB
Breast Cancer Res Treat; 2001 Aug; 68(3):225-37. PubMed ID: 11727959
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
